[Experimental and clinical studies of temafloxacin in the field of obstetrics and gynecology].

Temafloxacin (TMFX, TA-167) is a new quinolone antimicrobial agent that has a broad antibacterial spectrum against Gram-positive, Gram-negative and anaerobic bacteria. We obtained the following results from laboratory and clinical studies on TMFX. 1. TMFX showed good penetration into the female genital organs and Cmax's in various organs were 2.77-4.24 micrograms/g when 300 mg was administered, and these values were equal to or higher than Cmax in vein blood. 2. The clinical efficacy rate was 95.4% in a clinical study involving 219 cases. The bacterial eradication rate was 96.4% in 139 cases. 3. Nine cases of side effects and 1 case of abnormal change in laboratory findings were noted in 254 cases involved, but none of them was serious. Based on these findings, TMFX is expected to be a useful antimicrobial agent for the treatment of obstetric and gynecological infections.